RxSight Announces CFO Transition and Leadership Continuity Plan

RxSight ( (RXST) ) just unveiled an announcement.

On December 23, 2025, RxSight, Inc. entered into a transition agreement and release of claims with outgoing Chief Financial Officer Shelley Thunen, along with a consulting agreement that will take effect upon her separation from employment, under which she will provide transition services to the company. The leadership change, previously announced, is not expected to alter RxSight’s outlook or expectations for full-year 2025, with the company emphasizing that it remains focused on executing its strategic and operational priorities despite the CFO transition.

The most recent analyst rating on (RXST) stock is a Hold with a $12.50 price target. To see the full list of analyst forecasts on RxSight stock, see the RXST Stock Forecast page.

Spark’s Take on RXST Stock

According to Spark, TipRanks’ AI Analyst, RXST is a Neutral.

RxSight’s overall stock score is primarily influenced by its financial challenges, including negative profitability and revenue decline. While technical indicators show some positive momentum, the valuation remains unattractive due to the negative P/E ratio. The earnings call provided mixed signals with improvements in certain areas but highlighted significant revenue and net loss challenges.

To see Spark’s full report on RXST stock, click here.

More about RxSight

RxSight, Inc. operates in the medical technology sector, focusing on ophthalmic solutions, particularly products used in eye care and vision correction. The company targets the healthcare and vision care markets with technologies designed to improve patient outcomes and support ophthalmic surgeons and providers.

Average Trading Volume: 774,032

Technical Sentiment Signal: Hold

Current Market Cap: $494.6M

For an in-depth examination of RXST stock, go to TipRanks’ Overview page.